A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

NCT06963177 | Recruiting Phase 2

• 1 other identifier: GenSci048-205
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to evaluate the safety and efficacy of GenSci048 for moderate to severe endometriosis-associated pain treatment.

Conditions

Endometriosis-related Pain

Outcome Measures

Primary Outcomes (2)

• Change of dysmenorrhea (DYS) measured by Numeric Rating Scale (NRS)

  The NRS for overall endometriosis-associated pain ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

  baseline, week 24

• Change of non-menstrual pelvic pain (NMPP) measured by Numeric Rating Scale (NRS)

  The NRS for overall endometriosis-associated pain ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

  baseline, week 24

Secondary Outcomes (4)

• Change of DYS, NMPP, and dyspareunia (DYSP) measured by Numeric Rating Scale (NRS). The NRS for overall endometriosis-associated pain ranges from 0 (no pain) to 10 (severe pain). Higher scores mean a worse outcome.

  52 weeks

• Permitted rescue medication use.

  52 weeks

• Patient Global Impression of Change, Patient Global Impression of Change (minimum 1, maximum 7, higher score mean a worse outcome).

  Week 12、Week 24、Week 52

• Adverse Event

  up to approximately 56 weeks

Study Arms (2)

GenSci048

EXPERIMENTAL

GenSci048 subcutaneously (SC) every 4 weeks.

Drug: GenSci048

Placebo

PLACEBO COMPARATOR

Administered SC every 4 weeks.

Drug: Placebo

Interventions

GenSci048 DRUG

Administered SC.

GenSci048

Placebo DRUG

Administered SC.

Placebo

Eligibility Criteria

• Age: 18 Years - 49 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Pre-menopausal female participants, between 18 and 49 years of age, inclusive, at the time of signing informed consent.
• Participants must have a diagnosis of endometriosis within 10 years before screening.
• Have moderate to severe endometrial related pain.
• Have at least one regular, natural menstrual cycles (ranging from 21 to 35 days (inclusive)) before and during the screening period.
• Agree to switch from her usual analgesic medication to only that which is permitted in the study from the screening period to the end of treatment and agree to stop using other treatments for endometriosis.
• Agree to use non-hormonal contraception from the time of signing the informed consent until 4 weeks after the last dose of the study medication.

You may not qualify if:

• Participants who have previously received hysterectomy and/or bilateral oophorectomy, or plan to undergo these procedures during the study period.
• Participants who suffer from chronic pelvic and/or non-pelvic pain that is not caused by EM and require chronic analgesia or other chronic treatment, which is expected to affect the assessment of EAP.
• Pelvic ultrasound screening indicating a need for surgery or suspicion of malignancy.
• Participants with abnormal and undiagnosed vaginal and/or uterine bleeding within 3 months prior to screening.
• Participants who plan to schedule elective surgery during the study; or those who have had a surgery within 4 months prior to screening and need ongoing pain management.
• History of severe depression or post-traumatic stress disorder within the two years prior to screening, or history of any other severe mental disorder at any time.
• History of drug or alcohol abuse within the six months prior to screening.
• Participants who have participated in any other interventional clinical trial (including clinical trials of drugs and devices) within 1 month prior to screening.
• Have used a prohibited long-acting anesthetic or immediate-release anesthetic for more than 2 consecutive weeks for the treatment of endometriosis associated pain in the 6 months prior to screening.
• Participant is pregnant, breast feeding, or planning a pregnancy.

Sponsors & Collaborators

• Changchun GeneScience Pharmaceutical Co., Ltd.: lead

Study Sites (1)

Peking University First Hospital

Beijing, Beijing Municipality, 100000, China

RECRUITING

Central Study Contacts

Jingsi Li

CONTACT

+86 18301941524; lijingsi@genscigroup.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 28, 2025
• First Posted: May 8, 2025
• Study Start: May 26, 2025
• Primary Completion (Estimated): May 15, 2028
• Study Completion (Estimated): January 6, 2030
• Last Updated: August 12, 2025

Record last verified: 2025-08

Locations

CN (1)